This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Takeda-Shire merger-commitments waiver decision published by EU

( September 10, 2020, 07:59 GMT | Official Statement) -- MLex Summary: A European Commission decision from May this year to waive 2018 conditions imposed on Japan-based drugmaker Takeda's acquisition of Shire, was today released on commission's website. The EU antitrust authority in 2018 granted approval for the deal, asking Takeda to divest a biologic drug under development by Shire. But after a market investigation, the commission concluded that the divestment was no longer required, following changed market circumstances.The public version of the decision is attached. Case reference is M.8955. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login